Cargando…
NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma
Lung adenocarcinoma (LUAD) is the most prevalent histologic type of lung cancer, associated with a high incidence rate and substantial mortality rate worldwide. Accumulating evidence shows that the aberrant expression of neuromedin U (NMU) contributes to the initiation and progression of cancer. Her...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292091/ https://www.ncbi.nlm.nih.gov/pubmed/34336003 http://dx.doi.org/10.1155/2021/5031479 |
_version_ | 1783724777737814016 |
---|---|
author | Tang, Yan Hu, Chunsheng |
author_facet | Tang, Yan Hu, Chunsheng |
author_sort | Tang, Yan |
collection | PubMed |
description | Lung adenocarcinoma (LUAD) is the most prevalent histologic type of lung cancer, associated with a high incidence rate and substantial mortality rate worldwide. Accumulating evidence shows that the aberrant expression of neuromedin U (NMU) contributes to the initiation and progression of cancer. Herein, we explored whether NMU could be adopted as a new diagnostic and therapeutic marker in LUAD. The UALCAN and GEPIA web resources were employed to assess data on the NMU expression in LUAD. The STRING web resource was used to develop the PPI (protein-protein interaction) network of NMU, whereas Cytoscape was applied for module analysis. The Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of NMU and the interacting proteins were examined using the WebGestalt tool. Survival analysis was performed with the Kaplan-Meier plotter tool. Results revealed that the NMU expression in LUAD was significantly higher than in the nonmalignant tissues. Moreover, higher NMU levels were dramatically related to shorter overall survival, first progression survival, and postprogression survival. The specific gene mutations G45V, R143T, and F152L of NMU occurred in LUAD samples and were associated with a worse prognosis in patients. KEGG and western blot analyses demonstrated an association of NMU with the cell cycle and the cAMP signaling cascade. Bioinformatic analysis and the in vitro experiments implicated NMU as a promising prognostic signature and treatment target for LUAD. |
format | Online Article Text |
id | pubmed-8292091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-82920912021-07-31 NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma Tang, Yan Hu, Chunsheng Dis Markers Research Article Lung adenocarcinoma (LUAD) is the most prevalent histologic type of lung cancer, associated with a high incidence rate and substantial mortality rate worldwide. Accumulating evidence shows that the aberrant expression of neuromedin U (NMU) contributes to the initiation and progression of cancer. Herein, we explored whether NMU could be adopted as a new diagnostic and therapeutic marker in LUAD. The UALCAN and GEPIA web resources were employed to assess data on the NMU expression in LUAD. The STRING web resource was used to develop the PPI (protein-protein interaction) network of NMU, whereas Cytoscape was applied for module analysis. The Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of NMU and the interacting proteins were examined using the WebGestalt tool. Survival analysis was performed with the Kaplan-Meier plotter tool. Results revealed that the NMU expression in LUAD was significantly higher than in the nonmalignant tissues. Moreover, higher NMU levels were dramatically related to shorter overall survival, first progression survival, and postprogression survival. The specific gene mutations G45V, R143T, and F152L of NMU occurred in LUAD samples and were associated with a worse prognosis in patients. KEGG and western blot analyses demonstrated an association of NMU with the cell cycle and the cAMP signaling cascade. Bioinformatic analysis and the in vitro experiments implicated NMU as a promising prognostic signature and treatment target for LUAD. Hindawi 2021-07-12 /pmc/articles/PMC8292091/ /pubmed/34336003 http://dx.doi.org/10.1155/2021/5031479 Text en Copyright © 2021 Yan Tang and Chunsheng Hu. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tang, Yan Hu, Chunsheng NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma |
title | NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma |
title_full | NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma |
title_fullStr | NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma |
title_full_unstemmed | NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma |
title_short | NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma |
title_sort | nmu is a poor prognostic biomarker in patients with lung adenocarcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292091/ https://www.ncbi.nlm.nih.gov/pubmed/34336003 http://dx.doi.org/10.1155/2021/5031479 |
work_keys_str_mv | AT tangyan nmuisapoorprognosticbiomarkerinpatientswithlungadenocarcinoma AT huchunsheng nmuisapoorprognosticbiomarkerinpatientswithlungadenocarcinoma |